Navigation Links
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Date:9/18/2007

TOKYO, September 18 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that AD 337, an enantiomer of an approved, centrally acting, non-opioid, analgesic, has completed a Phase II proof of principle trial for the treatment of fibromyalgia syndrome (FMS).

The trial, a multi-centre, randomised, double-blind, placebo controlled, parallel group exploratory study, investigated the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in female subjects. In total, the trial enrolled 103 patients across 18 centres in the UK and Australia with the primary study endpoint being the difference in the Fibromyalgia Impact Questionnaire (FIQ) score, between active and placebo, after 4 weeks of treatment.

Results show that the study did not achieve a statistically significant outcome in its primary endpoint at 4 weeks. However statistical significance in FIQ was achieved at the 1 week time point and positive trends were seen throughout the study. In addition statistically significant measures in other efficacy assessments such as the Short Form McGill Pain Questionnaire and the Fibromyalgia Health Assessment Questionnaire (FHAQ) were seen at early time points. On balance it is concluded that AD 337 has some potential in the treatment of fibromyalgia syndrome.

AD 337 was well tolerated and there were no clinically significant changes in vital signs, biochemistry, haematology and cardiovascular parameters.

Commenting on these results Shinichi Tamura, CEO, said "This proof of principle study with an unoptimised formulation and dosing schedule and limited to four weeks in duration has demonstrated a degree of activity. Sosei will be evaluating these results to determine its approach to the possible further development of AD 337 in FMS and other potential indications."

Notes to Editors:

About Sosei

Sosei Group Corporation is a leading
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Mount Dora, Florida (PRWEB) April 23, 2015 ... announced that it intends to conduct a groundbreaking ... can begin to be reversed in as little ... researchers—using the science of metabolic and nutritional medicine—will ... conditions that cripple and destroy our aging brain. ...
(Date:4/23/2015)... April 23, 2015 WuXi PharmaTech (Cayman) Inc. ... and technology platform company serving the pharmaceutical, biotechnology and ... and the United States ... for the first quarter of 2015 after the New ... (which will be Thursday morning, May 14, 2015 Shanghai ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
(Date:4/23/2015)... 23, 2015 ReliantHeart's HeartAssist5® Ventricular Assist ... flow through the device) in real time, and this ... world’s leading provider of Machine to Machine (M2M) communications ... Flow via VADLink.com can be monitored by ... drop in flow below a minimum threshold, the patient ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... TOKYO, Japan, October 14 ... a biopharmaceutical company,today announces the assignment of the ... Limited, a UK biotechnology company and subsidiary of,PepTcell ... a well-known,drug, were shown by Sosei to have ...
... , SAN DIEGO, Oct. 13 SpectraScience, Inc. (OTC ... company, today announced that it has engaged Bielderman BVBA, ... clinical process for its Barrett,s esophageal cancer application under ... be used in the Company,s application to the Food ...
... (Nasdaq: CPHD ) today announced that it will report ... on Wednesday, October 28, 2009, after the close of the ... 2 p.m. Pacific Time on Wednesday, October 28, 2009, to ... visit Cepheid,s website at www.cepheid.com/investors at ...
Cached Biology Technology:Sosei Announces Deal With UK Biotech Company 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 3Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... metabolic pathway for breaking down glucose that could lead to ... The new pathway is intended to replace the ... reactions that nearly all organisms use to convert sugars into ... the six carbon atoms found in glucose into two-carbon molecules ...
... process required for repairing DNA breakage, scientists at the Duke ... deal with the barrage of damage that can contribute to ... week of Sept. 30, 2013, in the journal Proceedings ... work by the research team and identify new prospects for ...
... Davis Health System researchers have identified for the first ... sugar levels are abnormally high and causes irregular heartbeats, ... with heart failure and sudden cardiac death. ... the discovery helps explain why diabetes is a significant ...
Cached Biology News:UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2New insights into DNA repair process may spur better cancer therapies 2UC Davis researchers discover a biological link between diabetes and heart disease 2UC Davis researchers discover a biological link between diabetes and heart disease 3